Michael Lourenco Costa
Known title: Executive VP, CFO & TreasurerCIK: 0001838630
Michael Lourenco Costa's purchase track record
Michael Lourenco Costa has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/1/2023 | SBRA | $25K | +15.9% | +12.9% | +13.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SBRA | ▲ Buy | Grant | 4,158 | $0 | 8/31/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 4,200 | $0 | 5/29/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 4,005 | $0 | 2/27/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 22,848 | $0 | 2/10/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 85,690 | $0 | 1/8/2026 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 46,132 | $905K | 1/8/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 39,831 | $0 | 12/31/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 3,457 | $0 | 11/28/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 3,473 | $0 | 8/29/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 3,736 | $0 | 5/30/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 3,858 | $0 | 2/28/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 63,782 | $0 | 1/15/2025 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 15,783 | $271K | 1/8/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 37,477 | $0 | 12/27/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 2,429 | $0 | 11/29/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 2,624 | $0 | 8/30/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 3,004 | $0 | 5/31/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 3,089 | $0 | 2/29/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 23,209 | $0 | 1/31/2024 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 468 | $6K | 1/5/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 36,468 | $0 | 12/28/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 1,706 | $0 | 11/30/2023 | View on chart |
| SBRA | ▲ Buy | Open Market | 1,947 | $25K | 9/1/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 1,942 | $0 | 8/31/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 2,103 | $0 | 5/31/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 14,894 | $0 | 3/1/2023 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 5,151 | $61K | 3/1/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 1,939 | $0 | 2/28/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 4,437 | $0 | 1/28/2023 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 1,532 | $21K | 1/28/2023 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 1,008 | $13K | 1/4/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 34,777 | $0 | 12/27/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 1,016 | $0 | 11/30/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 859 | $0 | 8/31/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 897 | $0 | 5/31/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 916 | $0 | 2/28/2022 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 1,325 | $18K | 12/31/2021 | View on chart |
| SBRA | ▲ Buy | Grant | 24,696 | $0 | 12/28/2021 | View on chart |
| SBRA | ▲ Buy | Grant | 444 | $0 | 11/30/2021 | View on chart |
| SBRA | ▲ Buy | Grant | 353 | $0 | 8/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Sabra Health Care REIT analysts lower price targets
UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.
Sabra Health Care REIT analysts lower price targets. UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.